Sara Galimberti
Impact in
- Hematology top 0.2%
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
Papers in
- Hematology 159
- Multiple Myeloma Research and Treatments 62
- Chronic Myeloid Leukemia Treatments 50
- Acute Myeloid Leukemia Research 41
- Genetics 112
- Chronic Lymphocytic Leukemia Research 70
- Myeloproliferative Neoplasms: Diagnosis and Treatment 26
- Co-authors
- Mario PetriniRita FazziAntonio PalumboPellegrino MustoSimone PaciniMario BoccadoroFortunato MorabitoTommaso Caravita
- Journals
- Blood (44 papers)Leukemia Research (19 papers)Frontiers in Oncology (13 papers)Haematologica (11 papers)Acta Haematologica (9 papers)
- Partner nations
- ItalyUnited StatesCanada
In The Last Decade
Sara Galimberti
289 papers receiving 4.9k citations
Peers
Comparison fields: 5 of 135
- Hematology 2.2k
- Genetics 1.4k
- Oncology 1.7k
- Pathology and Forensic Medicine 847
- Immunology 745
Countries citing papers authored by Sara Galimberti
This map shows the geographic impact of Sara Galimberti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara Galimberti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara Galimberti more than expected).
Fields of papers citing papers by Sara Galimberti
This network shows the impact of papers produced by Sara Galimberti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara Galimberti. The network helps show where Sara Galimberti may publish in the future.
Co-authors
The 25 scholars most cited alongside Sara Galimberti, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 17 | |
| 2 | 2024 | 1 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 2 | |
| 5 | 2023 | 0 | |
| 6 | 2021 | 110 | |
| 7 | 2020 | 45 | |
| 8 | 2019 | 3 | |
| 9 | ATHEROTHROMBOTIC RISK ASSESSMENT DURING TYROSINE KINASE INHIBITORS TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS: NEW INSIGHT? | 2014 | 1 |
| 10 | Predictive role of WT1 and RPS14 expression in patients affected by myelodysplastic syndromes receiving azacitidine | 2013 | 2 |
| 11 | TCR REARRANGEMENTS ARE NOT ENOUGH FOR DISTINGUISHING THE CHURG-STRAUSS SYNDROME FROM THE HYPEREOSINOPHILIC SYNDROME | 2013 | 1 |
| 12 | 2011 | 179 | |
| 13 | 2010 | 124 | |
| 14 | HISTONE ACETHYLASE INHIBITORS VORINOSTAT AND ITF2357 EXERT A DEMETHYLATINGEFFECT ON THE MYELOMA CELL LINE U266 | 2010 | 2 |
| 15 | CD23 expression in plasma cell leukaemia | 2010 | 0 |
| 16 | 2009 | 3 | |
| 17 | CONTRAST ENHANCED ULTRASOUND SONOGRAPHY IN INTESTINAL ACUTE GRAFTVERSUS HOST DISEASE | 2009 | 1 |
| 18 | EFFICACY OF FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (FCR) REGIMEN FOL-LOWED BY ALEMTUZUMAB AS IN VIVO PURGING TOOL FOR PATIENTS WITH ADVANCEDCHRONIC LYMPHOCYTIC LEUKEMIA | 2007 | 2 |
| 19 | PS-341 (BORTEZOMIB) INHIBITS BOTH PROLIFERATION OF MEGAKARYOBLASTIC CELLSIN VITRO AND MK COLONIES PRODUCTION IN PATIENTS AFFECTED BY IDIOPATHICMYELOFIBROSIS | 2007 | 2 |
| 20 | 2006 | 137 |
About Sara Galimberti
Sara Galimberti is a scholar working on Hematology, Genetics, Oncology, Pathology and Forensic Medicine and Immunology, having authored 303 papers that have together received 5.0k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (70 papers), Multiple Myeloma Research and Treatments (62 papers), Lymphoma Diagnosis and Treatment (58 papers), Chronic Myeloid Leukemia Treatments (50 papers), Acute Myeloid Leukemia Research (41 papers), Protein Degradation and Inhibitors (28 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (26 papers) and Cancer Treatment and Pharmacology (20 papers). The work is most often cited by research in Hematology (2.2k citations), Genetics (1.4k citations), Oncology (1.7k citations), Pathology and Forensic Medicine (847 citations) and Immunology (745 citations). Sara Galimberti has collaborated with scholars based in Italy, United States and Canada. Frequent co-authors include Mario Petrini, Rita Fazzi, Antonio Palumbo, Pellegrino Musto, Simone Pacini, Mario Boccadoro, Fortunato Morabito, Tommaso Caravita, Enrico Orciuolo and Gabriele Buda. Their work appears in journals such as Blood, Leukemia Research, Frontiers in Oncology, Haematologica and Acta Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.